Genome Scanning and Tissue Microarrays for the Analysis of Molecular Mechanisms Underlying Hormone Therapy Failure in Prostate Cancer

  • Lukas Bubendorf
  • Olli-P. Kallioniemi
Conference paper

Abstract

Prostate cancer (PC) is the most frequent cancer among men in western countries (1). There is a considerable discrepancy between the prevalence of histological and clinical prostate cancer. More than 30% of all males over fifty have been shown to harbor histological (incidental) PC, but only 9% develop clinical disease during their life-time (2). Therefore, most of the histologically detectable early PCs do not progress to clinically detectable disease. Increased use of the serum PSA assays in screening and early diagnosis has caused a dramatic increase of newly detected prostate cancers during the early 1990’s (http://www-seer.ims.nci.nih.gov). Most tumors are now diagnosed at an early stage. However, up to 30% of of the patients still present with locally advanced or metastatic disease at the time of diagnosis (1). PC also remains the second most common cause of cancer deaths in men. This illustrates the inherent lethal nature of this disease, and the fact that advanced PC will remain a significant health problem. Androgen deprivation therapy can initially relieve symptoms in a large proportion of patients with advanced prostate cancer, but long-term cure is rarely achieved because the tumors eventually become hormone-refractory (after a few months or years), and efficient alternative systemic therapies are not yet available.

Keywords

Agar Paraffin Androgen eDNA 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ries LAG, Kosary CL, Hankey BF et al. (1998) SEER Cancer Statistics Review, 1973–1995, National Cancer Institute. Bethesda, MD.Google Scholar
  2. 2.
    Scardino PT, Robert WM, Liss AH (1992) Early detection of prostate cancer. Hum Pathol 23:211–222.PubMedCrossRefGoogle Scholar
  3. 3.
    Kallioniemi A, Kallioniemi OP, Sudar D et al. (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818–821.PubMedCrossRefGoogle Scholar
  4. 4.
    Rooney PH, Murray GI, Stevenson DAJ et al. (1999) Comparative genomic hybridization and chromosomal instability in solid tumors. Br J Cancer 80:862–873.PubMedCrossRefGoogle Scholar
  5. 5.
    Visakorpi T, Hyytinen E, Koivisto P et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401–406.PubMedCrossRefGoogle Scholar
  6. 6.
    Duggan DJ, Bittner M, Chen Y et al. (1999) Expression profiling using cDNA microarrays. Nat Genet 21:10–14.PubMedCrossRefGoogle Scholar
  7. 7.
    Nagabhushan M, Miller CM, Pretlow TP et al. (1996) CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 56:3042–3046.PubMedGoogle Scholar
  8. 8.
    Bubendorf L, Kolmer M, Kononen J et al. (in press) Molecular mechanisms of hormone therapy failure in human prostate cancer analyzed by a combination of cDNA and tissue microarrays. J Natl Cancer Inst.Google Scholar
  9. 9.
    Kononen J, Bubendorf L, Kallioniemi A et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847.PubMedCrossRefGoogle Scholar
  10. 10.
    Bubendorf L, Kononen J, Koivisto P et al. (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803–806.PubMedGoogle Scholar
  11. 11.
    Moch H, Schraml P, Bubendorf L et al. (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154:981–986.PubMedCrossRefGoogle Scholar
  12. 12.
    Schraml P, Kononen J, Bubendorf L et al. (in press) Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 2001

Authors and Affiliations

  • Lukas Bubendorf
  • Olli-P. Kallioniemi

There are no affiliations available

Personalised recommendations